サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1784075

組み換えタンパク質治療薬CDMOの世界市場

Recombinant Protein Therapeutics CDMO

出版日
ページ情報
英文 184 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.40円
組み換えタンパク質治療薬CDMOの世界市場
出版日: 2025年08月05日
発行: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.)
ページ情報: 英文 184 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

組み換えタンパク質治療薬CDMOの世界市場は2030年までに567億米ドルに達する見込み

2024年に256億米ドルと推定される組み換えタンパク質治療薬CDMOの世界市場は、2024～2030年の分析期間中に14.2%のCAGRで成長し、2030年には567億米ドルに達すると予測されます。本レポートで分析したセグメントの一つであるインターフェロンCDMOは、CAGR14.5%を記録し、分析期間終了時には249億米ドルに達すると予想されます。免疫賦活剤CDMOセグメントの成長率は、分析期間中CAGR 11.6%と推定されます。

米国市場は67億米ドルと推定、中国はCAGR13.3%で成長予測

米国の組み換えタンパク質治療薬CDMO市場は、2024年には67億米ドルになると推定されます。世界第2位の経済大国である中国は、2030年までに88億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは13.3%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ13.1%と12.2%と予測されています。欧州では、ドイツがCAGR 10.4%で成長すると予測されています。

世界の組み換えタンパク質治療薬CDMO市場- 主要動向と促進要因まとめ

CDMO（開発製造受託機関）が組換えタンパク質治療薬に欠かせない存在になりつつあるのはなぜか？

生物製剤や組換えタンパク質治療薬に対する需要の高まりが、医薬品開発・製造受託機関（CDMO）の拡大に拍車をかけています。CDMOは、バイオ医薬品企業の医薬品開発・製造を効率化する上で重要な役割を果たしています。モノクローナル抗体、サイトカイン、酵素、成長因子などの組換えタンパク質治療薬は、がん、自己免疫疾患、代謝性疾患、希少遺伝病など、幅広い疾患の治療に欠かせないものとなっています。しかし、タンパク質の発現、精製、規制遵守の複雑さは、医薬品メーカーにとって大きな課題となっています。その結果、製薬会社やバイオテクノロジー企業は、バイオプロセス開発、大規模製造、規制対応などの専門知識を提供する専門のCDMOに組換えタンパク質製造を委託するようになってきています。細胞株工学、高収率発現システム、高度な精製技術の台頭は、生産効率を高め、厳しい品質基準を満たすためにCDMOへの依存度をさらに高めています。加えて、個別化医療や次世代生物製剤が重視されるようになったことで、製薬会社は柔軟でスケーラブルな製造ソリューションを求めるようになり、CDMOはバイオ医薬品のエコシステムにおいて不可欠なパートナーとなっています。

技術の進歩は組換えタンパク質治療薬製造にどのような変化をもたらしているか？

バイオプロセス技術の進化により、組換えタンパク質生産の効率性と拡張性が大幅に向上し、CDMOは費用対効果を改善しながら高品質の治療薬を提供できるようになりました。CHO（チャイニーズハムスター卵巣）細胞、大腸菌、酵母、植物ベースのプラットフォームなどの発現系における革新は、タンパク質の収量、安定性、翻訳後修飾を最適化し、より精密でスケーラブルな製造を可能にしました。シングルユース・バイオリアクターと連続バイオプロセス技術は、コンタミネーションのリスクを減らし、バッチ間の一貫性を高め、生産スケジュールを最小化することで、生産ワークフローに革命をもたらしています。さらに、AI主導のプロセス分析とリアルタイム・モニタリング・システムは、予測的品質管理を可能にし、プロセスのばらつきを減らし、生産効率を向上させています。細胞培養と精製プロセスにおける自動化とロボティクスの採用は、業務の拡張性をさらに高め、CDMOが組換え生物製剤の需要増に対応できるようにしています。さらに、クロマトグラフィーベースの分離技術やメンブレンベースのろ過システムを含む下流の精製技術の進歩により、タンパク質の回収率が向上し、バイオ製造の全体的な効率が高まっています。このような技術的進歩により、CDMOは最高の規制・品質基準を維持しながら医薬品開発のタイムラインを加速させる重要なイネーブラーとして位置づけられています。

リコンビナント・タンパク質治療におけるCDMOの需要を牽引する市場動向とは？

バイオ医薬品製造におけるアウトソーシングへのシフトの増加は、コスト圧力、規制の複雑さ、専門的な専門知識の必要性によって、組み換えタンパク質治療薬市場の決定的な動向となっています。新興企業や中堅バイオテクノロジー企業は、社内に製造能力を持たないことが多いため、CDMOとの提携を活用して医薬品開発を加速し、設備投資リスクを軽減しています。バイオシミラーやバイオベッターの台頭は、製薬会社がブランド生物製剤に代わる費用対効果の高い代替品を求めているため、製造受託サービスへの需要をさらに押し上げています。さらに、遺伝子・細胞治療プログラムの拡大により、遺伝子組換えタンパク質生産を専門とするCDMO、特にウイルスベクター製造や細胞治療用培地開発に新たな機会が生まれています。また、分散型かつ柔軟な生物製剤製造戦略の推進により、モジュラー型および移動型の製造装置の採用が増加し、CDMOは新興治療薬に迅速に対応できる製造ソリューションを提供できるようになりました。さらに、FDAやEMAを含む世界の規制機関は、生物製剤に対するコンプライアンス要件を強化しており、バイオ製薬企業は、規制当局の承認や適正製造基準（GMP）ガイドラインのナビゲートにおいて確立された専門知識を持つCDMOに依存することを促しています。精密医療と次世代生物製剤が勢いを増す中、CDMOは研究と商業化のギャップを埋める極めて重要な役割を担っており、組換えタンパク質治療開発のためのエンドツーエンドのソリューションを提供しています。

組み換えタンパク質治療薬CDMO市場の主な成長促進要因は？

世界の組み換えタンパク質治療薬CDMO市場の成長は、生物製剤に対する需要の増加、バイオプロセス技術の急速な進歩、医薬品製造におけるアウトソーシングモデルの拡大など、いくつかの要因によって牽引されています。慢性疾患の有病率の上昇に加え、タンパク質ベースの治療法の採用が増加していることから、生産量が増加し、スケーラブルでコスト効率の高い製造ソリューションが必要とされています。シングルユース技術や連続バイオプロセスへのシフトにより、CDMOはバイオ医薬品企業の進化するニーズに応える柔軟で高収率の生産プラットフォームを提供できるようになりました。さらに、バイオシミラー開発の急増と迅速な生物学的製剤承認のための規制状況により、受託製造パートナーシップにとって有利な市場情勢が形成されています。GMP準拠の製造施設に対する投資の増加と、AI主導のプロセス最適化の採用が、市場の成長をさらに促進しています。バイオ医薬品のパイプラインの多様化が進み、CDMOのサービス内容も拡大していることから、組み換えタンパク質治療薬CDMO市場は持続的な成長が見込まれ、革新的な生物学的製剤を世界中の患者に提供する上で不可欠なサポートが提供されます。

セグメント

タイプ（インターフェロンCDMO、免疫賦活剤CDMO、ワクチンCDMO、成長ホルモンCDMO、その他のタイプ）、供給源（哺乳類系、微生物系、その他の供給源）、適応症（代謝疾患適応症、血液疾患適応症、がん適応症、免疫疾患適応症、感染症適応症、その他の適応症）

調査対象企業の例

  • 53Biologics
  • Batavia Biosciences B.V.
  • Biovian Oy
  • Catalent, Inc.
  • Cerbios-Pharma SA
  • Curia Global, Inc.
  • Enzene Biosciences Ltd
  • Etinpro（Beijing）Co.
  • Eurogentec
  • FUJIFILM Diosynth Biotechnologies
  • Goodwin Biotechnology
  • Grifols
  • HALIX B.V.
  • Icosagen AS
  • Lonza
  • MabPlex International
  • MicroProtein Technologies, Inc.
  • NorthX Biologics
  • Richter-Helm BioLogics
  • WuXi Biologics

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP32764

Global Recombinant Protein Therapeutics CDMO Market to Reach US$56.7 Billion by 2030

The global market for Recombinant Protein Therapeutics CDMO estimated at US$25.6 Billion in the year 2024, is expected to reach US$56.7 Billion by 2030, growing at a CAGR of 14.2% over the analysis period 2024-2030. Interferons CDMO, one of the segments analyzed in the report, is expected to record a 14.5% CAGR and reach US$24.9 Billion by the end of the analysis period. Growth in the Immunostimulating Agents CDMO segment is estimated at 11.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$6.7 Billion While China is Forecast to Grow at 13.3% CAGR

The Recombinant Protein Therapeutics CDMO market in the U.S. is estimated at US$6.7 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$8.8 Billion by the year 2030 trailing a CAGR of 13.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 13.1% and 12.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.4% CAGR.

Global Recombinant Protein Therapeutics CDMO Market - Key Trends & Drivers Summarized

Why Are Contract Development and Manufacturing Organizations (CDMOs) Becoming Integral to Recombinant Protein Therapeutics?

The growing demand for biologics and recombinant protein therapeutics has fueled the expansion of contract development and manufacturing organizations (CDMOs), which play a crucial role in streamlining drug development and production for biopharmaceutical companies. Recombinant protein therapies, including monoclonal antibodies, cytokines, enzymes, and growth factors, have become essential in treating a wide range of diseases, such as cancer, autoimmune disorders, metabolic conditions, and rare genetic diseases. However, the complexity of protein expression, purification, and regulatory compliance presents significant challenges for drug manufacturers. As a result, pharmaceutical and biotech companies are increasingly outsourcing their recombinant protein production to specialized CDMOs that offer expertise in bioprocess development, large-scale manufacturing, and regulatory support. The rise of cell-line engineering, high-yield expression systems, and advanced purification technologies has further increased the reliance on CDMOs to enhance production efficiency and meet stringent quality standards. Additionally, the growing emphasis on personalized medicine and next-generation biologics is driving pharmaceutical firms to seek flexible and scalable manufacturing solutions, making CDMOs indispensable partners in the biopharmaceutical ecosystem.

How Are Technological Advancements Transforming Recombinant Protein Therapeutics Manufacturing?

The evolution of bioprocessing technologies has significantly enhanced the efficiency and scalability of recombinant protein production, allowing CDMOs to deliver high-quality therapeutics with improved cost-effectiveness. Innovations in expression systems, such as CHO (Chinese hamster ovary) cells, E. coli, yeast, and plant-based platforms, have optimized protein yield, stability, and post-translational modifications, enabling more precise and scalable manufacturing. Single-use bioreactors and continuous bioprocessing techniques are revolutionizing production workflows by reducing contamination risks, increasing batch-to-batch consistency, and minimizing production timelines. Additionally, AI-driven process analytics and real-time monitoring systems are enabling predictive quality control, reducing process variability, and improving production efficiency. The adoption of automation and robotics in cell culture and purification processes has further enhanced operational scalability, allowing CDMOs to meet the growing demand for recombinant biologics. Moreover, downstream purification advancements, including chromatography-based separation techniques and membrane-based filtration systems, have improved protein recovery rates, enhancing overall biomanufacturing efficiency. These technological advancements are positioning CDMOs as key enablers in accelerating drug development timelines while maintaining the highest regulatory and quality standards.

What Market Trends Are Driving the Demand for CDMOs in Recombinant Protein Therapeutics?

The increasing shift toward outsourcing in biopharmaceutical manufacturing has been a defining trend in the recombinant protein therapeutics market, driven by cost pressures, regulatory complexities, and the need for specialized expertise. Startups and mid-sized biotech firms, which often lack in-house manufacturing capabilities, are leveraging CDMO partnerships to accelerate drug development and reduce capital investment risks. The rise of biosimilars and biobetters has further fueled demand for contract manufacturing services, as pharmaceutical companies seek cost-effective alternatives to branded biologics. Additionally, the expansion of gene and cell therapy programs has created new opportunities for CDMOs specializing in recombinant protein production, particularly in viral vector manufacturing and cell therapy media development. The push for decentralized and flexible biomanufacturing strategies has also led to increased adoption of modular and mobile production units, allowing CDMOs to offer rapid-response manufacturing solutions for emerging therapeutics. Furthermore, global regulatory agencies, including the FDA and EMA, are tightening compliance requirements for biologics, prompting biopharma firms to rely on CDMOs with established expertise in navigating regulatory approvals and Good Manufacturing Practice (GMP) guidelines. As precision medicine and next-generation biologics gain momentum, CDMOs are playing a pivotal role in bridging the gap between research and commercialization, providing end-to-end solutions for recombinant protein therapeutic development.

What Are the Key Growth Drivers of the Recombinant Protein Therapeutics CDMO Market?

The growth in the global recombinant protein therapeutics CDMO market is driven by several factors, including the increasing demand for biologics, rapid advancements in bioprocessing technologies, and the expansion of outsourcing models in pharmaceutical manufacturing. The rising prevalence of chronic diseases, coupled with the growing adoption of protein-based therapies, has led to increased production volumes, requiring scalable and cost-efficient manufacturing solutions. The shift toward single-use technologies and continuous bioprocessing has enabled CDMOs to offer flexible, high-yield production platforms that cater to the evolving needs of biopharmaceutical companies. Additionally, the surge in biosimilar development and regulatory support for expedited biologic approvals has created a favorable market landscape for contract manufacturing partnerships. The growing investments in GMP-compliant production facilities, coupled with the adoption of AI-driven process optimization, are further driving market growth. With increasing biopharma pipeline diversification and the expansion of CDMO service offerings, the recombinant protein therapeutics CDMO market is poised for sustained growth, providing essential support in bringing innovative biologic therapies to patients worldwide.

SCOPE OF STUDY:

The report analyzes the Recombinant Protein Therapeutics CDMO market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Interferons CDMO, Immunostimulating Agents CDMO, Vaccines CDMO, Growth Hormones CDMO, Other Types); Source (Mammalian Systems, Microbial Systems, Other Sources); Indication (Metabolic Disorders Indication, Hematological Disorders Indication, Oncology Indication, Immunological Disorders Indication, Infectious Diseases Indication, Other Indications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 42 Featured) -

  • 53Biologics
  • Batavia Biosciences B.V.
  • Biovian Oy
  • Catalent, Inc.
  • Cerbios-Pharma SA
  • Curia Global, Inc.
  • Enzene Biosciences Ltd
  • Etinpro (Beijing) Co.
  • Eurogentec
  • FUJIFILM Diosynth Biotechnologies
  • Goodwin Biotechnology
  • Grifols
  • HALIX B.V.
  • Icosagen AS
  • Lonza
  • MabPlex International
  • MicroProtein Technologies, Inc.
  • NorthX Biologics
  • Richter-Helm BioLogics
  • WuXi Biologics

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Recombinant Protein Therapeutics CDMO - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Outsourcing of Biologics Manufacturing Drives Growth in Recombinant Protein Therapeutics CDMOs
    • Expansion of Biosimilar Development Pipelines Strengthens Business Case for Specialized CDMO Services
    • Emergence of Complex Protein Modalities Throws the Spotlight on Advanced Process Development Capabilities
    • Increased Regulatory Stringency in Biopharmaceutical Production Spurs Demand for GMP-Compliant CDMOs
    • Biotech Startups Relying on Flexible Manufacturing Partnerships Accelerate CDMO Engagement
    • Growth in Targeted and Personalized Therapies Expands Custom Protein Manufacturing Requirements
    • Surge in Monoclonal Antibody and Fc-Fusion Protein Demand Generates Opportunities for Protein CDMOs
    • Technological Advancements in Upstream and Downstream Processing Enhance Scalability and Throughput
    • Adoption of Continuous Bioprocessing Platforms Drives Demand for Agile CDMO Infrastructures
    • Integration of AI and PAT Tools Improves Process Optimization and Accelerates Time-to-Market
    • Shift Toward Single-Use Bioreactor Systems Supports Cost-Efficient, Multi-Client Facility Models
    • Expansion of Cell Line Development and Expression Optimization Services Fuels Value-Added Differentiation
    • Increased Investment in Fill-Finish Capabilities Strengthens End-to-End CDMO Offerings
    • Strategic Collaborations Between Pharma and CDMOs Enhance Tech Transfer and Long-Term Capacity Planning
    • Diversification of Expression Systems Including Yeast, CHO, and E. coli Drives Multi-Platform Development Needs
    • Demand for Regional Manufacturing Hubs and Distributed Production Strengthens Localization Strategy
    • Focus on Intellectual Property Protection and Data Security Reinforces Trust in CDMO Engagements
    • Increased Pipeline of Rare Disease Biologics and Orphan Drugs Spurs Specialized CDMO Participation
    • Regulatory Harmonization Across Markets Enhances CDMO Expansion Opportunities Globally
    • M&A Activity Among Mid-Sized CDMOs and Global Pharma Players Expands Contract Manufacturing Capacity
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recombinant Protein Therapeutics CDMO Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Recombinant Protein Therapeutics CDMO by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Recombinant Protein Therapeutics CDMO by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Interferons CDMO by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Interferons CDMO by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Immunostimulating Agents CDMO by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Immunostimulating Agents CDMO by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Vaccines CDMO by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Vaccines CDMO by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Growth Hormones CDMO by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Growth Hormones CDMO by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hematological Disorders Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Hematological Disorders Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Oncology Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Oncology Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Immunological Disorders Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Immunological Disorders Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Infectious Diseases Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Infectious Diseases Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World 6-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Metabolic Disorders Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 25: World 6-Year Perspective for Metabolic Disorders Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Mammalian Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World 6-Year Perspective for Mammalian Systems by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Microbial Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 29: World 6-Year Perspective for Microbial Systems by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 30: World Recent Past, Current & Future Analysis for Other Sources by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 31: World 6-Year Perspective for Other Sources by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Recombinant Protein Therapeutics CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Recombinant Protein Therapeutics CDMO by Type - Interferons CDMO, Immunostimulating Agents CDMO, Vaccines CDMO, Growth Hormones CDMO and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA 6-Year Perspective for Recombinant Protein Therapeutics CDMO by Type - Percentage Breakdown of Value Sales for Interferons CDMO, Immunostimulating Agents CDMO, Vaccines CDMO, Growth Hormones CDMO and Other Types for the Years 2025 & 2030
    • TABLE 34: USA Recent Past, Current & Future Analysis for Recombinant Protein Therapeutics CDMO by Indication - Hematological Disorders Indication, Oncology Indication, Immunological Disorders Indication, Infectious Diseases Indication, Other Indications and Metabolic Disorders Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 35: USA 6-Year Perspective for Recombinant Protein Therapeutics CDMO by Indication - Percentage Breakdown of Value Sales for Hematological Disorders Indication, Oncology Indication, Immunological Disorders Indication, Infectious Diseases Indication, Other Indications and Metabolic Disorders Indication for the Years 2025 & 2030
    • TABLE 36: USA Recent Past, Current & Future Analysis for Recombinant Protein Therapeutics CDMO by Source - Mammalian Systems, Microbial Systems and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 37: USA 6-Year Perspective for Recombinant Protein Therapeutics CDMO by Source - Percentage Breakdown of Value Sales for Mammalian Systems, Microbial Systems and Other Sources for the Years 2025 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Recombinant Protein Therapeutics CDMO by Type - Interferons CDMO, Immunostimulating Agents CDMO, Vaccines CDMO, Growth Hormones CDMO and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada 6-Year Perspective for Recombinant Protein Therapeutics CDMO by Type - Percentage Breakdown of Value Sales for Interferons CDMO, Immunostimulating Agents CDMO, Vaccines CDMO, Growth Hormones CDMO and Other Types for the Years 2025 & 2030
    • TABLE 40: Canada Recent Past, Current & Future Analysis for Recombinant Protein Therapeutics CDMO by Indication - Hematological Disorders Indication, Oncology Indication, Immunological Disorders Indication, Infectious Diseases Indication, Other Indications and Metabolic Disorders Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Canada 6-Year Perspective for Recombinant Protein Therapeutics CDMO by Indication - Percentage Breakdown of Value Sales for Hematological Disorders Indication, Oncology Indication, Immunological Disorders Indication, Infectious Diseases Indication, Other Indications and Metabolic Disorders Indication for the Years 2025 & 2030
    • TABLE 42: Canada Recent Past, Current & Future Analysis for Recombinant Protein Therapeutics CDMO by Source - Mammalian Systems, Microbial Systems and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Canada 6-Year Perspective for Recombinant Protein Therapeutics CDMO by Source - Percentage Breakdown of Value Sales for Mammalian Systems, Microbial Systems and Other Sources for the Years 2025 & 2030
  • JAPAN
    • Recombinant Protein Therapeutics CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Recombinant Protein Therapeutics CDMO by Type - Interferons CDMO, Immunostimulating Agents CDMO, Vaccines CDMO, Growth Hormones CDMO and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan 6-Year Perspective for Recombinant Protein Therapeutics CDMO by Type - Percentage Breakdown of Value Sales for Interferons CDMO, Immunostimulating Agents CDMO, Vaccines CDMO, Growth Hormones CDMO and Other Types for the Years 2025 & 2030
    • TABLE 46: Japan Recent Past, Current & Future Analysis for Recombinant Protein Therapeutics CDMO by Indication - Hematological Disorders Indication, Oncology Indication, Immunological Disorders Indication, Infectious Diseases Indication, Other Indications and Metabolic Disorders Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Japan 6-Year Perspective for Recombinant Protein Therapeutics CDMO by Indication - Percentage Breakdown of Value Sales for Hematological Disorders Indication, Oncology Indication, Immunological Disorders Indication, Infectious Diseases Indication, Other Indications and Metabolic Disorders Indication for the Years 2025 & 2030
    • TABLE 48: Japan Recent Past, Current & Future Analysis for Recombinant Protein Therapeutics CDMO by Source - Mammalian Systems, Microbial Systems and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 49: Japan 6-Year Perspective for Recombinant Protein Therapeutics CDMO by Source - Percentage Breakdown of Value Sales for Mammalian Systems, Microbial Systems and Other Sources for the Years 2025 & 2030
  • CHINA
    • Recombinant Protein Therapeutics CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 50: China Recent Past, Current & Future Analysis for Recombinant Protein Therapeutics CDMO by Type - Interferons CDMO, Immunostimulating Agents CDMO, Vaccines CDMO, Growth Hormones CDMO and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China 6-Year Perspective for Recombinant Protein Therapeutics CDMO by Type - Percentage Breakdown of Value Sales for Interferons CDMO, Immunostimulating Agents CDMO, Vaccines CDMO, Growth Hormones CDMO and Other Types for the Years 2025 & 2030
    • TABLE 52: China Recent Past, Current & Future Analysis for Recombinant Protein Therapeutics CDMO by Indication - Hematological Disorders Indication, Oncology Indication, Immunological Disorders Indication, Infectious Diseases Indication, Other Indications and Metabolic Disorders Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: China 6-Year Perspective for Recombinant Protein Therapeutics CDMO by Indication - Percentage Breakdown of Value Sales for Hematological Disorders Indication, Oncology Indication, Immunological Disorders Indication, Infectious Diseases Indication, Other Indications and Metabolic Disorders Indication for the Years 2025 & 2030
    • TABLE 54: China Recent Past, Current & Future Analysis for Recombinant Protein Therapeutics CDMO by Source - Mammalian Systems, Microbial Systems and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: China 6-Year Perspective for Recombinant Protein Therapeutics CDMO by Source - Percentage Breakdown of Value Sales for Mammalian Systems, Microbial Systems and Other Sources for the Years 2025 & 2030
  • EUROPE
    • Recombinant Protein Therapeutics CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Recombinant Protein Therapeutics CDMO by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe 6-Year Perspective for Recombinant Protein Therapeutics CDMO by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 58: Europe Recent Past, Current & Future Analysis for Recombinant Protein Therapeutics CDMO by Type - Interferons CDMO, Immunostimulating Agents CDMO, Vaccines CDMO, Growth Hormones CDMO and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: Europe 6-Year Perspective for Recombinant Protein Therapeutics CDMO by Type - Percentage Breakdown of Value Sales for Interferons CDMO, Immunostimulating Agents CDMO, Vaccines CDMO, Growth Hormones CDMO and Other Types for the Years 2025 & 2030
    • TABLE 60: Europe Recent Past, Current & Future Analysis for Recombinant Protein Therapeutics CDMO by Indication - Hematological Disorders Indication, Oncology Indication, Immunological Disorders Indication, Infectious Diseases Indication, Other Indications and Metabolic Disorders Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Europe 6-Year Perspective for Recombinant Protein Therapeutics CDMO by Indication - Percentage Breakdown of Value Sales for Hematological Disorders Indication, Oncology Indication, Immunological Disorders Indication, Infectious Diseases Indication, Other Indications and Metabolic Disorders Indication for the Years 2025 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Recombinant Protein Therapeutics CDMO by Source - Mammalian Systems, Microbial Systems and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe 6-Year Perspective for Recombinant Protein Therapeutics CDMO by Source - Percentage Breakdown of Value Sales for Mammalian Systems, Microbial Systems and Other Sources for the Years 2025 & 2030
  • FRANCE
    • Recombinant Protein Therapeutics CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 64: France Recent Past, Current & Future Analysis for Recombinant Protein Therapeutics CDMO by Type - Interferons CDMO, Immunostimulating Agents CDMO, Vaccines CDMO, Growth Hormones CDMO and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: France 6-Year Perspective for Recombinant Protein Therapeutics CDMO by Type - Percentage Breakdown of Value Sales for Interferons CDMO, Immunostimulating Agents CDMO, Vaccines CDMO, Growth Hormones CDMO and Other Types for the Years 2025 & 2030
    • TABLE 66: France Recent Past, Current & Future Analysis for Recombinant Protein Therapeutics CDMO by Indication - Hematological Disorders Indication, Oncology Indication, Immunological Disorders Indication, Infectious Diseases Indication, Other Indications and Metabolic Disorders Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 67: France 6-Year Perspective for Recombinant Protein Therapeutics CDMO by Indication - Percentage Breakdown of Value Sales for Hematological Disorders Indication, Oncology Indication, Immunological Disorders Indication, Infectious Diseases Indication, Other Indications and Metabolic Disorders Indication for the Years 2025 & 2030
    • TABLE 68: France Recent Past, Current & Future Analysis for Recombinant Protein Therapeutics CDMO by Source - Mammalian Systems, Microbial Systems and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: France 6-Year Perspective for Recombinant Protein Therapeutics CDMO by Source - Percentage Breakdown of Value Sales for Mammalian Systems, Microbial Systems and Other Sources for the Years 2025 & 2030
  • GERMANY
    • Recombinant Protein Therapeutics CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 70: Germany Recent Past, Current & Future Analysis for Recombinant Protein Therapeutics CDMO by Type - Interferons CDMO, Immunostimulating Agents CDMO, Vaccines CDMO, Growth Hormones CDMO and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Germany 6-Year Perspective for Recombinant Protein Therapeutics CDMO by Type - Percentage Breakdown of Value Sales for Interferons CDMO, Immunostimulating Agents CDMO, Vaccines CDMO, Growth Hormones CDMO and Other Types for the Years 2025 & 2030
    • TABLE 72: Germany Recent Past, Current & Future Analysis for Recombinant Protein Therapeutics CDMO by Indication - Hematological Disorders Indication, Oncology Indication, Immunological Disorders Indication, Infectious Diseases Indication, Other Indications and Metabolic Disorders Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: Germany 6-Year Perspective for Recombinant Protein Therapeutics CDMO by Indication - Percentage Breakdown of Value Sales for Hematological Disorders Indication, Oncology Indication, Immunological Disorders Indication, Infectious Diseases Indication, Other Indications and Metabolic Disorders Indication for the Years 2025 & 2030
    • TABLE 74: Germany Recent Past, Current & Future Analysis for Recombinant Protein Therapeutics CDMO by Source - Mammalian Systems, Microbial Systems and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Germany 6-Year Perspective for Recombinant Protein Therapeutics CDMO by Source - Percentage Breakdown of Value Sales for Mammalian Systems, Microbial Systems and Other Sources for the Years 2025 & 2030
  • ITALY
    • TABLE 76: Italy Recent Past, Current & Future Analysis for Recombinant Protein Therapeutics CDMO by Type - Interferons CDMO, Immunostimulating Agents CDMO, Vaccines CDMO, Growth Hormones CDMO and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: Italy 6-Year Perspective for Recombinant Protein Therapeutics CDMO by Type - Percentage Breakdown of Value Sales for Interferons CDMO, Immunostimulating Agents CDMO, Vaccines CDMO, Growth Hormones CDMO and Other Types for the Years 2025 & 2030
    • TABLE 78: Italy Recent Past, Current & Future Analysis for Recombinant Protein Therapeutics CDMO by Indication - Hematological Disorders Indication, Oncology Indication, Immunological Disorders Indication, Infectious Diseases Indication, Other Indications and Metabolic Disorders Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 79: Italy 6-Year Perspective for Recombinant Protein Therapeutics CDMO by Indication - Percentage Breakdown of Value Sales for Hematological Disorders Indication, Oncology Indication, Immunological Disorders Indication, Infectious Diseases Indication, Other Indications and Metabolic Disorders Indication for the Years 2025 & 2030
    • TABLE 80: Italy Recent Past, Current & Future Analysis for Recombinant Protein Therapeutics CDMO by Source - Mammalian Systems, Microbial Systems and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Italy 6-Year Perspective for Recombinant Protein Therapeutics CDMO by Source - Percentage Breakdown of Value Sales for Mammalian Systems, Microbial Systems and Other Sources for the Years 2025 & 2030
  • UNITED KINGDOM
    • Recombinant Protein Therapeutics CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 82: UK Recent Past, Current & Future Analysis for Recombinant Protein Therapeutics CDMO by Type - Interferons CDMO, Immunostimulating Agents CDMO, Vaccines CDMO, Growth Hormones CDMO and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: UK 6-Year Perspective for Recombinant Protein Therapeutics CDMO by Type - Percentage Breakdown of Value Sales for Interferons CDMO, Immunostimulating Agents CDMO, Vaccines CDMO, Growth Hormones CDMO and Other Types for the Years 2025 & 2030
    • TABLE 84: UK Recent Past, Current & Future Analysis for Recombinant Protein Therapeutics CDMO by Indication - Hematological Disorders Indication, Oncology Indication, Immunological Disorders Indication, Infectious Diseases Indication, Other Indications and Metabolic Disorders Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: UK 6-Year Perspective for Recombinant Protein Therapeutics CDMO by Indication - Percentage Breakdown of Value Sales for Hematological Disorders Indication, Oncology Indication, Immunological Disorders Indication, Infectious Diseases Indication, Other Indications and Metabolic Disorders Indication for the Years 2025 & 2030
    • TABLE 86: UK Recent Past, Current & Future Analysis for Recombinant Protein Therapeutics CDMO by Source - Mammalian Systems, Microbial Systems and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: UK 6-Year Perspective for Recombinant Protein Therapeutics CDMO by Source - Percentage Breakdown of Value Sales for Mammalian Systems, Microbial Systems and Other Sources for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 88: Rest of Europe Recent Past, Current & Future Analysis for Recombinant Protein Therapeutics CDMO by Type - Interferons CDMO, Immunostimulating Agents CDMO, Vaccines CDMO, Growth Hormones CDMO and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Rest of Europe 6-Year Perspective for Recombinant Protein Therapeutics CDMO by Type - Percentage Breakdown of Value Sales for Interferons CDMO, Immunostimulating Agents CDMO, Vaccines CDMO, Growth Hormones CDMO and Other Types for the Years 2025 & 2030
    • TABLE 90: Rest of Europe Recent Past, Current & Future Analysis for Recombinant Protein Therapeutics CDMO by Indication - Hematological Disorders Indication, Oncology Indication, Immunological Disorders Indication, Infectious Diseases Indication, Other Indications and Metabolic Disorders Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Rest of Europe 6-Year Perspective for Recombinant Protein Therapeutics CDMO by Indication - Percentage Breakdown of Value Sales for Hematological Disorders Indication, Oncology Indication, Immunological Disorders Indication, Infectious Diseases Indication, Other Indications and Metabolic Disorders Indication for the Years 2025 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Recombinant Protein Therapeutics CDMO by Source - Mammalian Systems, Microbial Systems and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe 6-Year Perspective for Recombinant Protein Therapeutics CDMO by Source - Percentage Breakdown of Value Sales for Mammalian Systems, Microbial Systems and Other Sources for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Recombinant Protein Therapeutics CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 94: Asia-Pacific Recent Past, Current & Future Analysis for Recombinant Protein Therapeutics CDMO by Type - Interferons CDMO, Immunostimulating Agents CDMO, Vaccines CDMO, Growth Hormones CDMO and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Asia-Pacific 6-Year Perspective for Recombinant Protein Therapeutics CDMO by Type - Percentage Breakdown of Value Sales for Interferons CDMO, Immunostimulating Agents CDMO, Vaccines CDMO, Growth Hormones CDMO and Other Types for the Years 2025 & 2030
    • TABLE 96: Asia-Pacific Recent Past, Current & Future Analysis for Recombinant Protein Therapeutics CDMO by Indication - Hematological Disorders Indication, Oncology Indication, Immunological Disorders Indication, Infectious Diseases Indication, Other Indications and Metabolic Disorders Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Asia-Pacific 6-Year Perspective for Recombinant Protein Therapeutics CDMO by Indication - Percentage Breakdown of Value Sales for Hematological Disorders Indication, Oncology Indication, Immunological Disorders Indication, Infectious Diseases Indication, Other Indications and Metabolic Disorders Indication for the Years 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Recombinant Protein Therapeutics CDMO by Source - Mammalian Systems, Microbial Systems and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific 6-Year Perspective for Recombinant Protein Therapeutics CDMO by Source - Percentage Breakdown of Value Sales for Mammalian Systems, Microbial Systems and Other Sources for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 100: Rest of World Recent Past, Current & Future Analysis for Recombinant Protein Therapeutics CDMO by Type - Interferons CDMO, Immunostimulating Agents CDMO, Vaccines CDMO, Growth Hormones CDMO and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 101: Rest of World 6-Year Perspective for Recombinant Protein Therapeutics CDMO by Type - Percentage Breakdown of Value Sales for Interferons CDMO, Immunostimulating Agents CDMO, Vaccines CDMO, Growth Hormones CDMO and Other Types for the Years 2025 & 2030
    • TABLE 102: Rest of World Recent Past, Current & Future Analysis for Recombinant Protein Therapeutics CDMO by Indication - Hematological Disorders Indication, Oncology Indication, Immunological Disorders Indication, Infectious Diseases Indication, Other Indications and Metabolic Disorders Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 103: Rest of World 6-Year Perspective for Recombinant Protein Therapeutics CDMO by Indication - Percentage Breakdown of Value Sales for Hematological Disorders Indication, Oncology Indication, Immunological Disorders Indication, Infectious Diseases Indication, Other Indications and Metabolic Disorders Indication for the Years 2025 & 2030
    • TABLE 104: Rest of World Recent Past, Current & Future Analysis for Recombinant Protein Therapeutics CDMO by Source - Mammalian Systems, Microbial Systems and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of World 6-Year Perspective for Recombinant Protein Therapeutics CDMO by Source - Percentage Breakdown of Value Sales for Mammalian Systems, Microbial Systems and Other Sources for the Years 2025 & 2030

IV. COMPETITION